T a G Treatment Action Group Inc.

“A draft of form 990 was sent to members of the finance committee for review”

“Executive director's compensation is reviewed and approved by the board of directors.”

“Compensation of all employees except executive director is reviewed and approved by the executive director.”

“The organization's goverment documents are available upon request. Annual reports are available on the organization's website.”

“Tag works to ensure that all people with hiv receive lifesaving treatment, care, and information. We are science-based treatment activists working to expand and accelerate vital research and effective community engagement with research and policy institutions. Tag catalyzes open collective action by all affected communities, scientists, and policy makers to end aids.”

“Tb/hiv project: tuberculosis (tb) kills roughly 1.3 million people each year. Despite being curable, it is the leading cause of death for hiv-positive people globally. Hiv significantly increases the risk of developing tuberculosis disease. People at risk for both diseases require tuberculosis and hiv services that work together to address their needs. The treatment action groups tb/hiv project strengthens community-driven advocacy for better tb/hiv research, high-quality programs, and tb policies worldwide. The tb/hiv coinfection project educates, mobilizes and empowers hiv communities to increase community understanding of tb/hiv coinfection and to take action to reduce tb/hiv coinfection. The program works with researchers, community advocates, policymakers and global coalitions to increase the quantity and improve the quality of research that can lead to improved treatment; better tb prevention; new and precise tb diagnostics; and vaccines that may prevent tb infection.”

“Hepatitis c virus (hcv) project: hepatitis c virus (hcv) related liver disease has become a leading cause of death among hiv-positive people in the united states and europe. Globally, five million hiv-positive people are co-infected with hcv. Hiv worsens hcv disease progression and outcomes. The treatment action groups hcv project reviews the state of research on hcv mono-infection and coinfection, and advocates for better and safer treatments. The hcv project advocates for better clinical trial designs, access to treatment for all affected communities, and continually monitors standards of care for people with hcv mono- and coinfection. The project works in collaboration with hcv and hiv community, scientists, government, and drug companies to make lifesaving information and safer, more tolerable, and more effective hepatitis treatment available to all people who need it. In 2012 the hcv project expanded its scope to take on the challenge of accelerating international access to cutting-edge diagnosis and treatment for hcv, and is working with partners globally to implement this work, while continuing to work to accelerate the development and appropriate testing of new short-course combination all-oral cures for hcv.”

“Hiv project: each day, more than 4,000 people worldwide die of hiv disease. This immense public health failure can be attributed to a dense web of medical, political, and economic problems. The vast majority of the worlds 35 million hiv-positive people live in poor countries where many obstacles prevent the widespread distribution of hiv drugs. But even the most effective existing drugs have major shortcomings, and hiv-positive people everywhere need better treatment strategies. Tags hiv project reviews the state of research on anti-hiv drug discovery, development, dissemination, and post-marketing surveillance. The hiv project advocates for accelerated access to treatments; innovation in the development of treatments which are active against drug-resistant hiv; development of hiv treatments that are easier to take, that are less toxic, and/or represent a major therapeutic breakthrough such as a new drug class. Tag advocates for better post-marketing research on approved antiretroviral drugs to improve standards of care; works on domestic and international treatment guidelines; and educates and mobilizes policymakers, researchers, and the hiv community on hiv treatment research. Tag works with hiv community members, scientists, and policy makers to enhance public understanding of the science of hiv infection, address gaps in hiv research, critique research efforts, and foster cross-disciplinary collaborations with the aim of accelerating research into hiv pathogenesis and speeding the development of effective immune-based therapies, preventive technologies, with a particular focus research advocacy around a cure for hiv. In 2013, tag hired a hiv prevention research and policy coordinator to take on the task of tracking and analyzing resources devoted toward hiv prevention and combined prevention technologies. We advocate for ensuring local, state and national agencies and aids service organizations have increased awareness and knowledge of up-to-date prevention tools in an effort to set the groundwork for the eventual end of the hiv epidemic. Also, in 2013, tag initiated a project to revitalize the u.s. National hiv/aids strategy, working with activists, researchers, public health and government officials to capitalize on new science and policy developments to create a more ambitious u.s. Hiv/aids strategy in order to hasten the end of the hiv epidemic in the united states. Tags bsvc project brings together basic and clinical scientists, government officials, regulators, researchers, and community research advocates to work together to increase funding, attention, and basic and clinical science to identify strategies which will lead to an hiv cure. Finally, tag works with global and domestic partners for universal access to high-quality aids prevention, treatment, and care programs.”

“Loss on disposal of fixed assets -8,737.”

“The process has not changed since the prior year.”